SMAD3 and neoplasm: Particularly, ONECUT2 is overexpressed in poorly differentiated neuroendocrine prostate tumors, and its expression increases with tumor progression; in tumor cells, ONECUT2 acts as a regulator of hypoxia signaling and regulates HIF-1α binding to chromatin through SMAD3 activation [98].